Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
- Citation:
- J Clin Oncol vol 37 (35) 3425-35
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- To be presented at the spotlight session at the San Antonio Breast Cancer Symposium Meeting 2018, December 4-8, 2018, San Antonio, Texas.
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 9
- Parents:
- 2970
- Children:
- None
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U24CA196171; U10CA180868 (NRG), UG1CA189867 (NRG NCORP), U10CA180822, U24CA196067 (NRG Biospecimen)
- Corr. Author:
- Authors:
- Saranya Chumsri Zhuo Li Daniel J. Serie Afshin Mashadi-Hossein Gerardo Colon-Otero Nan Song Katherine L. Pogue-Geile Patrick G. Gavin Soonmyung Paik Alvaro Moreno-Aspitia Edith A. Perez E. Aubrey Thompson
- Networks:
- LAPS-MN026, NY021, PR028
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N9831, NSABP B-31
- Phases:
- 3
- Keywords: